

Supplementary Table S1. Serum cytokine levels in patients with Takayasu's arteritis in remission and in healthy controls.

Cytokines	Takayasu's arteritis (n=34)	Healthy controls (n=22)	<i>p</i>
IL-6, pg/ml	16.53 (11.10-30.59)	16.95 (11.73-20.76)	0.621
IL-1 β , pg/ml	5.19 (4.44-6.53)	5.20 (4.25-7.15)	0.873
TNF- α , pg/ml	15.95 (12.04-19.96)	17.33 (12.09-20.26)	0.546
IL-2, pg/ml	30.08 (23.83-38.93)	32.66 (23.66-43.76)	0.574
IL-12p70, pg/ml	13.20 (9.56-17.47)	13.14 (10.49-16.73)	0.980
IFN γ , pg/ml	27.11 (20.33-32.72)	28.49 (20.90-36.36)	0.847
IL-4, ng/ml	0.075 (0.047-0.112)	0.075 (0.060-0.011)	0.980
IL-5, pg/ml	10.24 (7.76-12.81)	9.72 (8.07-11.40)	0.597
IL-9, pg/ml	18.08 (14.55-21.13)	17.17 (12.38-20.32)	0.392
IL-13, pg/ml	311.61 \pm 136.09	256.55 \pm 108.89	0.117
IL-17A, pg/ml	18.59 (14.24-27.28)	23.99 (17.00-30.27)	0.279
IL17E, ng/ml	0.180 (0.147-0.240)	0.215 (0.162-0.282)	0.253
IL-17F, ng/ml	0.050 (0.037-0.070)	0.060 (0.030-0.080)	0.866
IL-21, pg/ml	42.08 (31.38-66.45)	49.41 (27.77-58.75)	0.860
IL-22, ng/ml	0.270 (0.220-0.315)	0.310 (0.255-0.362)	0.153
IL-23, ng/ml	3.64 (2.62-5.14)	4.56 (3.19-6.60)	0.217
IL-10, pg/ml	4.95 (3.92-7.42)	4.52 (3.49-5.48)	0.107

IFN: interferon; IL: interleukin; TNF: tumor necrosis factor.

Supplementary Table S2. Multivariate linear logistic regression models to analyse factors that influence serum cytokine levels.

Variables	β coefficient	95%CI	<i>p</i>
TNF-α			
Age	-0.039	-0.223 to 0.145	0.653
Female sex	0.079	-14.059 to 14.216	0.991
Angiographic type V	6.433	-1.746 to 14.611	0.112
Ischemic events	1.955	-4.126 to 8.035	0.497
Daily prednisone dose	0.062	-0.119 to 0.244	0.208
Use of immunosuppressive and biological agents	-6.898	-14.707 to 0.911	0.078
IL-6			
Age	-0.036	-0.244 to 0.172	0.714
Female sex	3.216	-12.731 to 19.163	0.668
Angiographic type V	14.126	4.901 to 23.352	0.006*
Ischemic events	-0.542	-7.401 to 6.317	0.866
Daily prednisone dose	-0.286	-0.491 to -0.081	0.010*
Use of immunosuppressive and biological agents	2.195	-6.614 to 11.003	0.597
IL-4			
Age	0.000	-0.001 to 0.001	0.371
Female sex	-0.058	-0.126 to 0.010	0.087
Angiographic type V	0.064	0.025 to 0.103	0.004*
Ischemic events	0.030	0.000 to 0.059	0.048*
Daily prednisone dose	-0.002	-0.002 to -0.001	0.002*
Use of immunosuppressive and biological agents	-0.044	-0.082 to -0.007	0.024*
IL-17A			
Age	0.015	-0.168 to 0.199	0.857
Female sex	-4.653	-18.702 to 9.395	0.484
Angiographic type V	11.099	2.972 to 19.227	0.012*
Ischemic events	3.998	-2.045 to 10.040	0.175
Daily prednisone dose	-0.220	-0.400 to -0.039	0.021*
Use of immunosuppressive and biological agents	-4.068	-11.828 to 3.692	0.276
IL-17E			
Age	8.830×10^{-5}	-0.001 to 0.001	0.824
Female sex	-0.031	-0.096 to 0.033	0.312
Angiographic type V	0.064	0.027 to 0.102	0.003*
Ischemic events	0.044	0.016 to 0.072	0.005*
Daily prednisone dose	-0.001	-0.002 to -0.001	0.003*
Use of immunosuppressive and biological agents	-0.046	-0.082 to -0.010	0.017*
IL-17F			
Age	-8.865×10^{-5}	-0.001 to 0.000	0.700
Female sex	0.012	-0.026 to 0.049	0.511
Angiographic type V	0.028	0.006 to 0.050	0.016*
Ischemic events	0.011	-0.005 to 0.027	0.166
Daily prednisone dose	0.000	-0.001 to 0.000	0.445
Use of immunosuppressive and biological agents	-0.017	-0.038 to 0.004	0.097
IL-21			
Age	0.007	-0.388 to 0.401	0.972
Female sex	16.510	-13.734 to 46.755	0.257
Angiographic type V	26.166	8.669 to 43.663	0.007*
Ischemic events	12.784	-0.224 to 25.793	0.053
Daily prednisone dose	-0.169	-0.558 to 0.220	0.363
Use of immunosuppressive and biological agents	-11.696	-28.402 to 5.010	0.153
IL-22			
Age	0.000	-0.096 to 0.062	0.647
Female sex	-0.017	-0.001 to 0.001	0.653
Angiographic type V	0.062	0.016 to 0.108	0.012*
Ischemic events	0.039	0.005 to 0.072	0.029*
Daily prednisone dose	-0.001	-0.002 to 0.000	0.011*
Use of immunosuppressive and biological agents	-0.041	-0.085 to 0.002	0.062
IL-23			
Age	-0.024	-0.024 to 0.022	0.924
Female sex	-0.609	-2.375 to 1.157	0.467
Angiographic type V	1.860	0.839 to 2.882	0.002*
Ischemic events	1.163	0.404 to 1.923	0.006*
Daily prednisone dose	-0.036	-0.058 to -0.013	0.005*
Use of immunosuppressive and biological agents	-0.986	-1.961 to -0.011	0.048*

*Significant *p* values; 95%CI: 95% confidence interval.